These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 9308240)

  • 1. Structural constraints for DNA recognition by Myc and other b-HLH-ZIP proteins: design of oncoprotein analogues.
    Takemoto C; Fisher DE
    Gene Expr; 1995; 4(6):311-7. PubMed ID: 7549463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative control of the Myc protein by the stress-responsive kinase Pak2.
    Huang Z; Traugh JA; Bishop JM
    Mol Cell Biol; 2004 Feb; 24(4):1582-94. PubMed ID: 14749374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperation between bHLH transcription factors and histones for DNA access.
    Michael AK; Stoos L; Crosby P; Eggers N; Nie XY; Makasheva K; Minnich M; Healy KL; Weiss J; Kempf G; Cavadini S; Kater L; Seebacher J; Vecchia L; Chakraborty D; Isbel L; Grand RS; Andersch F; Fribourgh JL; Schübeler D; Zuber J; Liu AC; Becker PB; Fierz B; Partch CL; Menet JS; Thomä NH
    Nature; 2023 Jul; 619(7969):385-393. PubMed ID: 37407816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains.
    Speltz TE; Qiao Z; Swenson CS; Shangguan X; Coukos JS; Lee CW; Thomas DM; Santana J; Fanning SW; Greene GL; Moellering RE
    Nat Biotechnol; 2023 Apr; 41(4):541-551. PubMed ID: 36302987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additivity in protein-DNA interactions: how good an approximation is it?
    Benos PV; Bulyk ML; Stormo GD
    Nucleic Acids Res; 2002 Oct; 30(20):4442-51. PubMed ID: 12384591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin tagged dominant negative induces degradation of B-ZIP proteins.
    Rios-Doria E; Chatterjee R; Zhao J; Rishi V; Vinson C
    Biochem Biophys Res Commun; 2012 Aug; 424(3):624-8. PubMed ID: 22789849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics.
    Urnov FD; Rebar EJ; Reik A; Pandolfi PP
    EMBO Rep; 2002 Jul; 3(7):610-5. PubMed ID: 12101091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
    Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
    Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of dominant negatives to bHLHZip proteins that inhibit DNA binding.
    Krylov D; Echlin DR; Taparowsky EJ; Vinson C
    Curr Top Microbiol Immunol; 1997; 224():169-77. PubMed ID: 9308240
    [No Abstract]   [Full Text] [Related]  

  • 10. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
    Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
    EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taking myc to the max.
    Turner R
    Nat Struct Biol; 2003 Mar; 10(3):157. PubMed ID: 12605219
    [No Abstract]   [Full Text] [Related]  

  • 14. Design and properties of a Myc derivative that efficiently homodimerizes.
    Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
    Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.